Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B

Ratings ESG MSCI

Ratings Haisco Pharmaceutical Group Co., Ltd.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • According to MSCI, the company's ESG score for its industry is poor.
Highlights: Haisco Pharmaceutical Group Co., Ltd.
  • The company's profit outlook over the next few years is a strong asset.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Haisco Pharmaceutical Group Co., Ltd.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 112.94 times its estimated earnings per share for the ongoing year.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Haisco Pharmaceutical Group Co., Ltd. SectorChina
Fundamentals -
Growth
Revenue growth
EPS growth
FCF growth-
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency-
ROA-
ROCE-
ROE
Financial Health-
Gearing-
Leverage-
Capital Intensity
Balance sheet growth-
Long Term balance sheet growth-
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Haisco Pharmaceutical Group Co., Ltd. SectorChina
Global Valuation -
Enterprise value-
EV/Revenue-
EV/EBITDA-
EV/FCF-
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT-
CAPEX/Revenue
More ratings

Rating Consensus

Haisco Pharmaceutical Group Co., Ltd. SectorChina
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Haisco Pharmaceutical Group Co., Ltd. SectorChina
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence-
Surprise rates

Rating Revisions

Haisco Pharmaceutical Group Co., Ltd. SectorChina
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
8.33B -
B
- -
866B
A
454B
BBB
387B
AA
296B
AA
268B
A
243B
AAA
215B
A
203B
A
174B
A
Average 311.41B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. 002653 Stock
  4. Ratings Haisco Pharmaceutical Group Co., Ltd.